Eversheds Sutherland Advises Azurity Pharmaceuticals on Acquisition of Sebela Bowel Prep Franchise

"Eversheds Sutherland advised Azurity Pharmaceuticals on its acquisition of Sebela’s Bowel Prep Franchise, which includes two leading bowel-preparation therapies for colonoscopies. The acquisition expands Azurity’s U.S. product offerings, advances access to medicines for overlooked patients and brings more than 50 commercial and support employees from Sebela."

Eversheds Sutherland advised Azurity Pharmaceuticals on its acquisition of Sebela’s bowel preparation franchise. The transaction transfers Sebela’s bowel prep franchise, including two leading bowel-preparation therapies used for colonoscopies, to Azurity Pharmaceuticals. The strategic acquisition further strengthens Azurity’s commitment to serving overlooked patients by advancing access to medicines. By integrating Sebela’s bowel prep franchise, Azurity will expand its product offerings and capabilities for healthcare providers and patients in the United States. The acquisition also brings into Azurity more than 50 colleagues from Sebela’s commercial and support teams. Eversheds Sutherland represented Azurity Pharmaceuticals with a team composed by: Partner Mike Voynich (Corporate); Partner Pete Pappas (Intellectual Property); Special Counsel Anna Halsey (Intellectual Property); Senior Associate Adam Byrne (Corporate); Associate Haley Klass (Corporate).

Eversheds Sutherland Advises Azurity Pharmaceuticals on Acquisition of Sebela Bowel Prep Franchise

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads